Genmab AS Documents
Documents
0
Ticker
GMAB
ISIN
US3723032062
Genmab AS SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Genmab AS Documents 2026
This page contains all official documents and SEC filings for Genmab AS stock (GMAB, ISIN: US3723032062). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Genmab AS's regulatory filings.
Genmab AS Stock analysis
Genmab AS Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions.